$Emerging role of multikinase inhibitors for refractory thyroid cancer$
Código QR

Emerging role of multikinase inhibitors for refractory thyroid cancer

Cesar A Perez,1 Belisario A Arango,1 Michel Velez,1 Luis E Raez,2 Edgardo S Santos11University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, USA; 2Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL, USAAbstract: Thyroid cancer incidence continues...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Perez CA, Arango BA, Velez M, Raez LE, Santos ES
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3179f4c79c1e45caa8c0a2a829772923
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3179f4c79c1e45caa8c0a2a829772923
record_format	dspace
spelling	oai:doaj.org-article:3179f4c79c1e45caa8c0a2a8297729232021-12-02T04:17:09ZEmerging role of multikinase inhibitors for refractory thyroid cancer1177-54751177-5491https://doaj.org/article/3179f4c79c1e45caa8c0a2a8297729232012-08-01T00:00:00Zhttp://www.dovepress.com/emerging-role-of-multikinase-inhibitors-for-refractory-thyroid-cancer-a10635https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Cesar A Perez,1 Belisario A Arango,1 Michel Velez,1 Luis E Raez,2 Edgardo S Santos11University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, USA; 2Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL, USAAbstract: Thyroid cancer incidence continues to increase, remaining the most common endocrine malignancy. The need for effective systemic therapies combined with high incidence of driver mutations and overexpression of molecular pathways make refractory thyroid cancer an ideal candidate for treatment with novel agents. Multikinase inhibitors have caused a paradigm shift in the treatment of patients with advanced iodine-refractory thyroid cancer. These agents have shown to be the most effective systemic therapy for this disease not only causing prolonged responses but also improving survival. The activity of these agents inhibiting several pathways simultaneously, such as rearranged during transfection protooncogene, mitogen-activated protein kinase, and angiogenesis, can probably explain the effectiveness in controlling the progression of this malignancy. Several of these agents are currently on clinical studies in patients with differentiated and medullary thyroid cancer and most of them are showing promising clinical activity. With the approval of vandetanib for the treatment of medullary thyroid cancer, a new era in the management of this disease has begun. The molecular rationale for the use of these drugs for thyroid cancer is discussed as well as their promising clinical results.Keywords: axitinib, cabozantinib, lenvatinib, mitogen-activated protein kinase (MAPK), motesanib, pazopanib, thyroid cancer, vandetanib, vascular endothelial growth factor receptor-2 (VEGFR2)Perez CAArango BAVelez MRaez LESantos ESDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 257-265 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Perez CA Arango BA Velez M Raez LE Santos ES Emerging role of multikinase inhibitors for refractory thyroid cancer
description	Cesar A Perez,1 Belisario A Arango,1 Michel Velez,1 Luis E Raez,2 Edgardo S Santos11University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, USA; 2Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL, USAAbstract: Thyroid cancer incidence continues to increase, remaining the most common endocrine malignancy. The need for effective systemic therapies combined with high incidence of driver mutations and overexpression of molecular pathways make refractory thyroid cancer an ideal candidate for treatment with novel agents. Multikinase inhibitors have caused a paradigm shift in the treatment of patients with advanced iodine-refractory thyroid cancer. These agents have shown to be the most effective systemic therapy for this disease not only causing prolonged responses but also improving survival. The activity of these agents inhibiting several pathways simultaneously, such as rearranged during transfection protooncogene, mitogen-activated protein kinase, and angiogenesis, can probably explain the effectiveness in controlling the progression of this malignancy. Several of these agents are currently on clinical studies in patients with differentiated and medullary thyroid cancer and most of them are showing promising clinical activity. With the approval of vandetanib for the treatment of medullary thyroid cancer, a new era in the management of this disease has begun. The molecular rationale for the use of these drugs for thyroid cancer is discussed as well as their promising clinical results.Keywords: axitinib, cabozantinib, lenvatinib, mitogen-activated protein kinase (MAPK), motesanib, pazopanib, thyroid cancer, vandetanib, vascular endothelial growth factor receptor-2 (VEGFR2)
format	article
author	Perez CA Arango BA Velez M Raez LE Santos ES
author_facet	Perez CA Arango BA Velez M Raez LE Santos ES
author_sort	Perez CA
title	Emerging role of multikinase inhibitors for refractory thyroid cancer
title_short	Emerging role of multikinase inhibitors for refractory thyroid cancer
title_full	Emerging role of multikinase inhibitors for refractory thyroid cancer
title_fullStr	Emerging role of multikinase inhibitors for refractory thyroid cancer
title_full_unstemmed	Emerging role of multikinase inhibitors for refractory thyroid cancer
title_sort	emerging role of multikinase inhibitors for refractory thyroid cancer
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/3179f4c79c1e45caa8c0a2a829772923
work_keys_str_mv	AT perezca emergingroleofmultikinaseinhibitorsforrefractorythyroidcancer AT arangoba emergingroleofmultikinaseinhibitorsforrefractorythyroidcancer AT velezm emergingroleofmultikinaseinhibitorsforrefractorythyroidcancer AT raezle emergingroleofmultikinaseinhibitorsforrefractorythyroidcancer AT santoses emergingroleofmultikinaseinhibitorsforrefractorythyroidcancer
_version_	1718401302759735296

Emerging role of multikinase inhibitors for refractory thyroid cancer

Ejemplares similares